Logo image of NLSP

NLS PHARMACEUTICS LTD (NLSP) Stock Fundamental Analysis

NASDAQ:NLSP - Nasdaq - CH1384053976 - Common Stock - Currency: USD

1.85  -0.1 (-5.13%)

After market: 1.9 +0.05 (+2.7%)

Fundamental Rating

1

Overall NLSP gets a fundamental rating of 1 out of 10. We evaluated NLSP against 198 industry peers in the Pharmaceuticals industry. NLSP may be in some trouble as it scores bad on both profitability and health. NLSP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NLSP had negative earnings in the past year.
NLSP had a negative operating cash flow in the past year.
NLSP had negative earnings in each of the past 5 years.
NLSP had a negative operating cash flow in each of the past 5 years.
NLSP Yearly Net Income VS EBIT VS OCF VS FCFNLSP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

The Return On Assets of NLSP (-552.58%) is worse than 94.95% of its industry peers.
Industry RankSector Rank
ROA -552.58%
ROE N/A
ROIC N/A
ROA(3y)-348.14%
ROA(5y)-411.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NLSP Yearly ROA, ROE, ROICNLSP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NLSP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NLSP Yearly Profit, Operating, Gross MarginsNLSP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

NLSP has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, NLSP has less shares outstanding
NLSP has a worse debt/assets ratio than last year.
NLSP Yearly Shares OutstandingNLSP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
NLSP Yearly Total Debt VS Total AssetsNLSP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -108.73, we must say that NLSP is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NLSP (-108.73) is worse than 93.43% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -108.73
ROIC/WACCN/A
WACCN/A
NLSP Yearly LT Debt VS Equity VS FCFNLSP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 0.15 indicates that NLSP may have some problems paying its short term obligations.
The Current ratio of NLSP (0.15) is worse than 95.45% of its industry peers.
NLSP has a Quick Ratio of 0.15. This is a bad value and indicates that NLSP is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of NLSP (0.15) is worse than 94.95% of its industry peers.
Industry RankSector Rank
Current Ratio 0.15
Quick Ratio 0.15
NLSP Yearly Current Assets VS Current LiabilitesNLSP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 19.12% over the past year.
EPS 1Y (TTM)19.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NLSP will show a very strong growth in Earnings Per Share. The EPS will grow by 40.37% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y89.47%
EPS Next 2Y40.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NLSP Yearly EPS VS EstimatesNLSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NLSP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NLSP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NLSP Price Earnings VS Forward Price EarningsNLSP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NLSP Per share dataNLSP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as NLSP's earnings are expected to grow with 40.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.37%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NLSP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NLS PHARMACEUTICS LTD

NASDAQ:NLSP (5/23/2025, 8:40:43 PM)

After market: 1.9 +0.05 (+2.7%)

1.85

-0.1 (-5.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)12-13 2022-12-13/bmo
Inst Owners13.04%
Inst Owner Change0%
Ins Owners24.77%
Ins Owner ChangeN/A
Market Cap3.66M
Analysts43.33
Price TargetN/A
Short Float %6.92%
Short Ratio1.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.72
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-1.98
FCFYN/A
OCF(TTM)-1.98
OCFYN/A
SpS0
BVpS-4.68
TBVpS-4.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -552.58%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-348.14%
ROA(5y)-411.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.15
Quick Ratio 0.15
Altman-Z -108.73
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)133.33%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.66%
EPS Next Y89.47%
EPS Next 2Y40.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y69.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y69.58%
OCF growth 3YN/A
OCF growth 5YN/A